The Syntara website can be found at and is current for all investor information from 4 December 2023, with select historical information provided for ease of use.

The Pharmaxis website is current for all investor information until 4 December 2023.

The Pharmaxis mannitol business unit (Bronchitol and Aridol) was sold to Arna Pharma Pty Ltd on 18 October 2023. The Arna Pharma website is

Recent Highlights

Sale of mannitol respiratory business and launch of Syntara

Pharmaxis has announced details of the sale of its mannitol respiratory business which manufactures and supplies Aridol and Bronchitol to global markets and the formation of Syntara, a clinical stage drug development company primarily focusing on treatments for haematological malignancies (blood-related cancers).

In a major restructure the mannitol business will be sold to pharmaceutical manufacturing specialist, Arna Pharma  with residual net exit costs of less than A$1m. and core expenses reduced by more than 60%, saving the company over A$14m per year.

Syntara will have five planned clinical studies to deliver results in high unmet need diseases by mid-2025. (The new company name is subject to approval by shareholders at the company AGM in November.)

Read more here.
Watch an interview with CEO Gary Phillips outlining the changes here.